Clinical Study Results
Where can I learn more about this study?
You can find more information about this study on the websites listed below. If a full report of the
study results is available, it can also be found here.
• www.clinicaltrials.gov. Once you are on this website, type “NCT02586987” into the search
box, and click “Search”.
• www.clinicaltrialsregister.eu. Once you are on the website, click “Home and Search”,
then type “2016-003780-19” in the search box, and click “Search”.
• www.AstraZenecaClinicalTrials.com. Once you are on the website, type “D1345C00003”
into the search box, and click “Find a Study”.
Full Trial Title: A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and
Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in
Combination with MEDI4736 and Selumetinib in Combination with MEDI4736 and Tremelimumab
in Patients with Advanced Solid Tumours
AstraZeneca Protocol Number: D1345C00003
AstraZeneca sponsored this study and has its headquarters at
1800 Concord Pike in Wilmington, Delaware.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you
Clinical study participants and their families belong to a large community of people who take part
in clinical research around the world. They help researchers answer important health questions
and find medical treatments for patients.
The Center for Information & Study on Clinical Research
Participation (CISCRP) is a non-profit organization focused
on educating and informing the public about clinical research
participation. CISCRP is not involved in recruiting participants for
clinical studies, nor is it involved in conducting clinical studies.
CISCRP
One Liberty Square, Suite 1100 • Boston, MA 02109
1-877-MED-HERO • www.ciscrp.org
Version 1.0 2020_01_03
12